Independent science sleuths have uncovered more than 100 suspicious images in the antibody catalogue of Thermo Fisher Scientific, a leading life sciences tool provider. The findings, reported by Nature News, raise new questions about quality control in the commercial research reagents market.
The investigation focused on images that appeared duplicated, rotated, or otherwise manipulated across multiple product listings. Such irregularities can undermine the reproducibility of experiments that rely on these antibodies, a long-standing concern in biomedical research.
Thermo Fisher has not yet publicly commented on the specific allegations. The company, which acquired the catalogue through its purchase of Life Technologies and other firms, has previously stated it takes product integrity seriously.
The implications extend beyond one vendor. With thousands of researchers depending on commercial antibodies, this case underscores the need for more rigorous pre-publication vetting and post-market surveillance of critical research tools.
Critics argue that profit incentives may conflict with quality assurance in the antibody industry, where catalogues can contain tens of thousands of products with varying validation.